321 related articles for article (PubMed ID: 24637722)
1. CCN2 enhances resistance to cisplatin-mediating cell apoptosis in human osteosarcoma.
Tsai HC; Huang CY; Su HL; Tang CH
PLoS One; 2014; 9(3):e90159. PubMed ID: 24637722
[TBL] [Abstract][Full Text] [Related]
2. YM155 inhibits tumor growth and enhances chemosensitivity to cisplatin in osteosarcoma.
Gao JZ; Chen FH; Wang L; Wei H; Meng SL
Eur Rev Med Pharmacol Sci; 2015; 19(11):2062-9. PubMed ID: 26125270
[TBL] [Abstract][Full Text] [Related]
3. P-Glycoprotein Overexpression Is Associated With Cisplatin Resistance in Human Osteosarcoma.
He C; Sun Z; Hoffman RM; Yang Z; Jiang Y; Wang L; Hao Y
Anticancer Res; 2019 Apr; 39(4):1711-1718. PubMed ID: 30952710
[TBL] [Abstract][Full Text] [Related]
4. CTGF increases drug resistance to paclitaxel by upregulating survivin expression in human osteosarcoma cells.
Tsai HC; Huang CY; Su HL; Tang CH
Biochim Biophys Acta; 2014 May; 1843(5):846-54. PubMed ID: 24462773
[TBL] [Abstract][Full Text] [Related]
5. Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.
He C; Liu C; Wang L; Sun Y; Jiang Y; Hao Y
Cell Death Dis; 2019 Jan; 10(2):65. PubMed ID: 30683853
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma.
Zhao G; Cai C; Yang T; Qiu X; Liao B; Li W; Ji Z; Zhao J; Zhao H; Guo M; Ma Q; Xiao C; Fan Q; Ma B
PLoS One; 2013; 8(1):e53906. PubMed ID: 23372675
[TBL] [Abstract][Full Text] [Related]
7. Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma.
Fan GT; Ling ZH; He ZW; Wu SJ; Zhou GX
Biochem Biophys Res Commun; 2021 May; 554():214-221. PubMed ID: 33813077
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Stim1 expression is associated with acquired chemo-resistance of cisplatin in osteosarcoma cells.
Sun X; Wei Q; Cheng J; Bian Y; Tian C; Hu Y; Li H
Hum Cell; 2017 Jul; 30(3):216-225. PubMed ID: 28326487
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA‑22 regulates autophagy and apoptosis in cisplatin resistance of osteosarcoma.
Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Sun L; Sun C; Feng W; Guo SB
Mol Med Rep; 2020 Nov; 22(5):3911-3921. PubMed ID: 33000186
[TBL] [Abstract][Full Text] [Related]
10. Secreted clusterin (sCLU) regulates cell proliferation and chemosensitivity to cisplatin by modulating ERK1/2 signals in human osteosarcoma cells.
Huang H; Wang L; Li M; Wang X; Zhang L
World J Surg Oncol; 2014 Aug; 12():255. PubMed ID: 25106434
[TBL] [Abstract][Full Text] [Related]
11. CTGF increases matrix metalloproteinases expression and subsequently promotes tumor metastasis in human osteosarcoma through down-regulating miR-519d.
Tsai HC; Su HL; Huang CY; Fong YC; Hsu CJ; Tang CH
Oncotarget; 2014 Jun; 5(11):3800-12. PubMed ID: 25003330
[TBL] [Abstract][Full Text] [Related]
12. HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma.
Xiao X; Wang W; Li Y; Yang D; Li X; Shen C; Liu Y; Ke X; Guo S; Guo Z
J Exp Clin Cancer Res; 2018 Aug; 37(1):201. PubMed ID: 30153855
[TBL] [Abstract][Full Text] [Related]
13. miR-223/Hsp70/JNK/JUN/miR-223 feedback loop modulates the chemoresistance of osteosarcoma to cisplatin.
Tang Q; Yuan Q; Li H; Wang W; Xie G; Zhu K; Li D
Biochem Biophys Res Commun; 2018 Mar; 497(3):827-834. PubMed ID: 29432736
[TBL] [Abstract][Full Text] [Related]
14. miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.
Zhou Y; Huang Z; Wu S; Zang X; Liu M; Shi J
J Exp Clin Cancer Res; 2014 Jan; 33(1):12. PubMed ID: 24468065
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of beclin1 affects the chemotherapeutic sensitivity of osteosarcoma.
Wu W; Li W; Zhou Y; Zhang C
Int J Clin Exp Pathol; 2014; 7(10):7114-22. PubMed ID: 25400807
[TBL] [Abstract][Full Text] [Related]
16. Sensitization of osteosarcoma cell line SaOS-2 to chemotherapy by downregulating survivin.
Zou J; Gan M; Mao N; Zhu X; Shi Q; Yang H
Arch Med Res; 2010 Apr; 41(3):162-9. PubMed ID: 20682173
[TBL] [Abstract][Full Text] [Related]
17. LncRNA-SARCC sensitizes osteosarcoma to cisplatin through the miR-143-mediated glycolysis inhibition by targeting Hexokinase 2.
Wen JF; Jiang YQ; Li C; Dai XK; Wu T; Yin WZ
Cancer Biomark; 2020; 28(2):231-246. PubMed ID: 32508321
[TBL] [Abstract][Full Text] [Related]
18. The ERK/eIF4F/Bcl-XL pathway mediates SGP-2 induced osteosarcoma cells apoptosis in vitro and in vivo.
Zhang Z; Zheng Y; Zhu R; Zhu Y; Yao W; Liu W; Gao X
Cancer Lett; 2014 Oct; 352(2):203-13. PubMed ID: 25025927
[TBL] [Abstract][Full Text] [Related]
19. Anticancer potential of TUG1 knockdown in cisplatin-resistant osteosarcoma through inhibition of MET/Akt signalling.
Zhou Q; Hu T; Xu Y
J Drug Target; 2020 Feb; 28(2):204-211. PubMed ID: 31305159
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA LINC00161 sensitises osteosarcoma cells to cisplatin-induced apoptosis by regulating the miR-645-IFIT2 axis.
Wang Y; Zhang L; Zheng X; Zhong W; Tian X; Yin B; Tian K; Zhang W
Cancer Lett; 2016 Nov; 382(2):137-146. PubMed ID: 27609068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
